{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T01:36:37Z","timestamp":1792287397749,"version":"4.4.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:sec>\n            <jats:title>Objectives:<\/jats:title>\n            <jats:p>Epithelial ovarian cancer is one of the commonest gynecologic cancers and one with the highest mortality. This retrospective cohort study was done to identify predictors of outcomes in platinum-sensitive relapsed ovarian cancer patients (PS-ROC).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Data regarding baseline characters, laboratory findings, therapeutic details and survival outcomes was obtained from the medical records of PS-ROC patients presented between January 2015 and December 2019. Prognostic score was constructed using factors which were significant on multivariate analysis to predict survival outcomes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A total of 71 (PS-ROC) patients were included in the study with a median age of 50 years. Relapse treatment was either chemotherapy alone (n=53, 75%) or chemotherapy plus surgery (n=18, 25%). The estimated progression-free survival (PFS) and overall survival were 10 and 29 months, respectively. The overall response rate after treatment of relapse was 59%. Prognostic score was created with the 3 factors (each scoring 1 point) which were predictive of PFS (higher lymphocyte-monocyte ratio, longer platinum-free interval and secondary cytoreduction). Patients with low score (0,1) had better PFS than those with higher score (2,3) (13 vs. 7\u2009mo [<jats:italic toggle=\"yes\">P<\/jats:italic>=0.0001]).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>A composite prognostic score could predict outcomes in PS-ROC and potentially identify a subgroup with very poor prognosis. Future studies with a greater number of patients are needed to validate these findings. This information could help tailor more intense therapies to the high-risk patients and attempt to improve outcomes and serve as stratification factors for prospective trials.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/coc.0000000000000830","type":"journal-article","created":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T20:29:58Z","timestamp":1622752198000},"page":"434-441","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["A Simple, Novel Prognostic Score in Platinum Sensitive Relapsed Ovarian Cancer"],"prefix":"10.1097","volume":"44","author":[{"given":"Luxitaa","family":"Goenka","sequence":"first","affiliation":[{"name":"Medical Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thejeshwar","family":"Nakka","sequence":"additional","affiliation":[{"name":"Medical Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biswajit","family":"Dubashi","sequence":"additional","affiliation":[{"name":"Medical Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smita","family":"Kayal","sequence":"additional","affiliation":[{"name":"Medical Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasanth","family":"Penumadu","sequence":"additional","affiliation":[{"name":"Surgical Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Latha","family":"Chaturvedula","sequence":"additional","affiliation":[{"name":"Obstetrics and Gynecology, JIPMER, Puducherry, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pampapati","family":"Veena","sequence":"additional","affiliation":[{"name":"Obstetrics and Gynecology, JIPMER, Puducherry, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayalakshmi","family":"Durairaj","sequence":"additional","affiliation":[{"name":"Obstetrics and Gynecology, JIPMER, Puducherry, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasanth","family":"Ganesan","sequence":"additional","affiliation":[{"name":"Medical Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,6,3]]},"reference":[{"key":"R1-20250527","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer"},{"key":"R2-20250527","doi-asserted-by":"crossref","first-page":"1179299X19860815","DOI":"10.1177\/1179299X19860815","article-title":"Chemotherapy resistance in advanced ovarian cancer patients","volume":"11","author":"Pokhriyal","year":"2019","journal-title":"Biomark Cancer"},{"issue":"suppl 4","key":"R3-20250527","doi-asserted-by":"crossref","first-page":"iv259","DOI":"10.1093\/annonc\/mdy157","article-title":"Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Ledermann","year":"2018","journal-title":"Ann Oncol"},{"key":"R4-20250527","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00280-017-3501-8","article-title":"Advances in ovarian cancer therapy","volume":"81","author":"Cortez","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"key":"R5-20250527","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S1359-6349(15)70003-0","article-title":"Introduction to managing patients with recurrent ovarian cancer","volume":"12","author":"Gabra","year":"2014","journal-title":"EJC Suppl"},{"key":"R6-20250527","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13048-019-0579-0","article-title":"Maintenance therapy for recurrent epithelial ovarian cancer: current therapies and future perspectives\u2212a review","volume":"12","author":"Gupta","year":"2019","journal-title":"J Ovarian Res"},{"key":"R7-20250527","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ygyno.2014.02.038","article-title":"\u201cPlatinum resistant\u201d ovarian cancer: what is it, who to treat and how to measure benefit?","volume":"133","author":"Davis","year":"2014","journal-title":"Gynecol Oncol"},{"key":"R8-20250527","doi-asserted-by":"crossref","first-page":"31","DOI":"10.14740\/jcgo488w","article-title":"Ovarian cancer: post-relapse survival and prognostic factors","volume":"7","author":"Miyoshi","year":"2018","journal-title":"J Clin Gynecol Obstet"},{"key":"R9-20250527","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1902626","article-title":"Secondary surgical cytoreduction for recurrent ovarian cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N Engl J Med"},{"issue":"suppl","key":"R10-20250527","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1200\/JCO.2017.35.15_suppl.5501","article-title":"Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III\/ENGOT ov20","volume":"35","author":"Du Bois","year":"2017","journal-title":"J Clin Oncol"},{"key":"R11-20250527","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/IGC.0b013e31820aaafd","article-title":"Prospective validation study of a predictive score for operability of recurrent ovarian cancer: The Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO","volume":"21","author":"Harter","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"R12-20250527","doi-asserted-by":"crossref","first-page":"e000039","DOI":"10.1136\/esmoopen-2016-000039","article-title":"Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio before chemotherapy as potential prognostic factors in patients with newly diagnosed epithelial ovarian cancer","volume":"1","author":"Badora-Rybicka","year":"2016","journal-title":"ESMO Open"},{"key":"R13-20250527","doi-asserted-by":"crossref","first-page":"289","DOI":"10.7150\/jca.13432","article-title":"The lymphocyte-monocyte ratio predicts patient survival and aggressiveness of ovarian cancer","volume":"7","author":"Eo","year":"2016","journal-title":"J Cancer"},{"key":"R14-20250527","doi-asserted-by":"crossref","first-page":"43001","DOI":"10.1038\/srep43001","article-title":"Preoperative red cell distribution width and neutrophil-to-lymphocyte ratio predict survival in patients with epithelial ovarian cancer","volume":"7","author":"Li","year":"2017","journal-title":"Sci Rep"},{"key":"R15-20250527","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","article-title":"Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG)","volume":"21","author":"Rustin","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"R16-20250527","doi-asserted-by":"crossref","first-page":"737","DOI":"10.7150\/jca.17668","article-title":"Peripheral blood lymphocyte-to-monocyte ratio as a prognostic factor in advanced epithelial ovarian cancer: a multicenter retrospective study","volume":"8","author":"Zhu","year":"2017","journal-title":"J Cancer"},{"key":"R17-20250527","doi-asserted-by":"crossref","first-page":"101174","DOI":"10.1016\/j.redox.2019.101174","article-title":"Targeting immune cells for cancer therapy","volume":"25","author":"Gun","year":"2019","journal-title":"Redox Biol"},{"key":"R18-20250527","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1479-5876-10-33","article-title":"Absolute lymphocyte count is associated with survival in ovarian cancer independent of tumor-infiltrating lymphocytes","volume":"10","author":"Milne","year":"2012","journal-title":"J Transl Med"},{"key":"R19-20250527","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1159\/000438523","article-title":"Prognostic role of tumor-infiltrating lymphocytes in lung cancer: a meta-analysis","volume":"37","author":"Geng","year":"2015","journal-title":"Cell Physiol Biochem"},{"key":"R20-20250527","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s40425-016-0165-6","article-title":"Clinical significance of tumor-infiltrating lymphocytes in breast cancer","volume":"4","author":"Stanton","year":"2016","journal-title":"J Immunother Cancer"},{"key":"R21-20250527","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1158\/1940-6207.CAPR-16-0209","article-title":"Targeting inflammation in cancer prevention and therapy","volume":"9","author":"Todoric","year":"2016","journal-title":"Cancer Prev Res Phila Pa"},{"key":"R22-20250527","doi-asserted-by":"crossref","first-page":"1596004","DOI":"10.1080\/2162402X.2019.1596004","article-title":"Interaction of tumor-associated macrophages and cancer chemotherapy","volume":"8","author":"Larionova","year":"2019","journal-title":"Oncoimmunology"},{"key":"R23-20250527","first-page":"21","article-title":"Role of monocyte count and neutrophil-to-lymphocyte ratio in survival of oral cancer patients","volume":"21","author":"Bobdey","year":"2017","journal-title":"Int Arch Otorhinolaryngol"},{"key":"R24-20250527","first-page":"3423","article-title":"AGO Score as a predictor of surgical outcome at secondary cytoreduction in patients with ovarian cancer","volume":"35","author":"Muallem","year":"2015","journal-title":"Anticancer Res"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/COC.0000000000000830","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T17:08:13Z","timestamp":1748365693000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/COC.0000000000000830"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,3]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0000000000000830","relation":{},"ISSN":["0277-3732"],"issn-type":[{"value":"0277-3732","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6,3]]}}}